Most used medication on Medicare value negotiation checklist: See the highest 3


Bottles of the drug Jardiance, made by Eli Lilly and Firm, sit on a counter at a pharmacy in Provo, Utah, January 9, 2020.

George Frey | Reuters

Two blood thinners and a diabetes remedy are the medication most generally utilized by Medicare beneficiaries amongst a checklist of 10 medication that will probably be topic to value negotiations between producers and Medicare. 

The Biden administration unveiled the much-awaited checklist Tuesday, kicking off a course of that goals to decrease drug prices for older adults within the U.S. The checklist names medication with the best spending for Medicare Half D, which covers prescription medicines, for the interval from June 1, 2022, to Might 31, 2023.

Bristol-Myers Squibb‘s blood thinner Eliquis was essentially the most extensively used throughout that point interval, with 3.7 million Medicare enrollees utilizing it, in response to a reality sheet from the Facilities for Medicare and Medicaid Providers, or CMS. 

Eliquis, co-developed by Pfizer, is used to stop blood clotting and cut back the danger of stroke.

The second most used drug was Boehringer Ingelheim’s Jardiance, which lowers blood sugar for individuals with Kind 2 diabetes. Practically 1.6 million Medicare enrollees used Jardiance throughout the identical time interval, in response to the actual fact sheet. 

Johnson & Johnson’s blood thinner Xarelto was third, as about 1.3 million beneficiaries used the remedy throughout that point.

Medicare Half D additionally spent extra on these three medication throughout the time interval than it did on the seven different medicines on the checklist. The plan spent $16.5 billion on Eliquis, roughly $7 billion on Jardiance and $6 billion on Xarelto, in response to CMS.

In whole, the ten medicines accounted for $50.5 billion, or about 20%, of whole Half D prescription drug prices from June 2022 to Might 2023, CMS mentioned.

Round 50.5 million sufferers are presently enrolled in Half D plans, in response to well being coverage analysis group KFF. Greater than 8.2 million use the ten medication on the checklist. 

Drugmakers need to signal agreements to hitch the negotiations by Oct. 1. CMS will then make an preliminary value provide to producers in February 2024, and people corporations have a month to simply accept or make a counteroffer. 

The negotiations will finish in August 2024, with agreed-upon costs revealed on Sept. 1, 2024. The decreased costs will not go into impact till January 2026. 


Supply hyperlink

Leave a comment